Dewpoint Therapeutics and ConcertAI form drug development partnership

FDA debuts precheck manufacturing program to boost domestic drug development

FDA has launched a venture in onshoring domestic drug development called the Precheck Pilot Program.

February 06, 2026

Labcorp and Roche collaborate to expand access to advanced precision testing

Labcorp announced its first U.S. commercial laboratory with an agreement to implement Roche’s cobas Mass Spec solution. This collaboration introduces fully automated mass spectrometry into routine clinical practice—accelerating turnaround times, improving accuracy, and expanding access to advanced diagnostics for patients and providers nationwide.

January 30, 2026

Vol.52 No.04

Drugs & Targets

HanchorBio and WuXi Biologics form partnership to advance next-generation bi-and multi-functional fusion protein pipeline

HanchorBio, a global clinical-stage biotechnology company, and WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization, jointly announced the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline.

January 30, 2026

Vol.52 No.04

Drugs & Targets

Verana Health and COTA merge to accelerate research-ready oncology real-world evidence

Verana Health and COTA Inc. are merging with the aim of providing data and software solutions for real-world insights that accelerate clinical research, expedite treatment options, and improve patient care.

January 16, 2026

Vol.52 No.02

In Brief

American Center for Cures and BlueCloudX collaborate to accelerate cures, modernize healthcare and clinical research

American Center for Cures and BlueCloudX announced a strategic collaboration aimed at accelerating the development of cures for major diseases while dramatically reducing the time, cost, and complexity of clinical research.

January 09, 2026

Vol.52 No.1

Drugs & Targets

Niowave expands global agreement with AstraZeneca for 10-year actinium-225 supply

Niowave Inc. and AstraZeneca are expanding their existing supply agreement to a 10-year commitment to deliver actinium-225, following AstraZeneca’s decision to exercise its option to increase capacity.

January 09, 2026

Vol.52 No.1

Dewpoint Therapeutics and ConcertAI form drug development partnership

YOU MAY BE INTERESTED IN

FDA debuts precheck manufacturing program to boost domestic drug development

Labcorp and Roche collaborate to expand access to advanced precision testing

HanchorBio and WuXi Biologics form partnership to advance next-generation bi-and multi-functional fusion protein pipeline

Verana Health and COTA merge to accelerate research-ready oncology real-world evidence

American Center for Cures and BlueCloudX collaborate to accelerate cures, modernize healthcare and clinical research

Niowave expands global agreement with AstraZeneca for 10-year actinium-225 supply

Renew today!

Subscriber content

Never miss an issue!

Login